Uncategorized Archives - Page 39 of 145

MondayJan 30, 2023 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports Promising Prophylactic Results from Preclinical Proof-of-Concept NanoAb COVID-19 Study

BiondVax’s preclinical proof-of-concept study was designed to mimic a real-world situation regarding at-risk groups, including the elderly, people with comorbidities, the immunocompromised, travelers, those attending densely packed social events, and front-line healthcare workers The study shows promising prophylactic results with hamsters receiving BiondVax’s inhaled NanoAb three hours before infection experiencing no significant weight loss over the six-day trial; follows previously reported data showing successful use of NanoAb as COVID-19 therapeutic First-in-human Phase 1/2a clinical trial is planned for later this year Focused on the development, manufacture, and commercialization of innovative NanoAb immunotherapeutic products, BiondVax Pharmaceuticals (NASDAQ: BVXV) recently announced additional…

ThursdayJan 26, 2023 9:45 am

MetAlert, Inc. (MLRT) Planned Acquisition of TrakTec LLC Adds Superior Radio Frequency-Based Tracking Technology to Portfolio of Location-Based Solutions

MetAlert recently announced the planned acquisition of TrakTec LLC, a Florida-based leader in location awareness technology for consumer and business applications The acquisition is expected to add several products to MetAlert’s existing suite of products, one of which is an RFID and Bluetooth-enabled tracking technology called SafetyNet(R) The SafetyNet Tracking System comprises the SafetyNet Bracelets that patients wear, and a receiver-antenna combo used by police departments and first responders The Chelmsford Police Department in Massachusetts recently reported it had successfully located a missing senior citizen with dementia because of its participation in the SafetyNet program The department has, over time,…

ThursdayJan 26, 2023 9:00 am

Silo Pharma Inc. (NASDAQ: SILO) Provides Update on UCSF Psylocibin Clinical Trial

SILO recently provided status update on its sponsored clinical trial with UCSF examining psilocybin’s effects on inflammation Targeted patient populations from study may provide support for development and use of psilocybin as a therapeutic to treat inflammatory conditions Data collection from all study groups expected by April 2023 SILO additionally evaluating its ketamine formulation through its partnership agreement with Zylö Therapeutics Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company that fuses traditional medicine with psychedelics, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”) examining the effect of psilocybin on…

TuesdayJan 24, 2023 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Combats Rising Heart Disease Numbers by Leading Out in Heart-Attack Detection Space

Rates of cardiovascular risk factors, disease and heart attacks projected to increase significantly HeartBeam offers a personal, portable and easy-to-use heart-attack detection solution “Our HeartBeam AIMI and HeartBeam AIMIGo solutions will transform the way patients and doctors detect heart attacks,” states CEO With heart disease consistently being the leading cause of death in the United States (https://ibn.fm/kDLwz), companies such as HeartBeam (NASDAQ: BEAT) that are focusing on solutions are gaining both attention and support. As a cardiac technology company, HeartBeam is leading the way in identifying heart attacks by developing a personal, portable and easy-to-use heart-attack detection solution. HeartBeam’s efforts…

MondayJan 23, 2023 12:00 pm

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19

Current monoclonal antibody therapies less effective against emerging COVID-19 variants BiondVax is developing an inhaled nanosized antibody (NanoAb) therapy for COVID-19 with human clinical Phase 1/2a results anticipated in 2023 The global monoclonal antibodies market was valued at $185.5 billion in 2021 and is projected to grow at a CAGR of 11.3% due to the rising prevalence of chronic diseases and demand for biologics The biologics market size was valued at $366.5 billion in 2021 and is expected to reach $719.94 billion by 2030 According to a new study, new COVID-19 subvariants have become dominant in recent months, rendering some…

MondayJan 23, 2023 9:45 am

MetAlert, Inc. (MLRT) In Strong Position Entering 2023 According to CEO Patrick Bertagna

MetAlert’s CEO, Patrick Bertagna, while appearing in an interview presented by Sequire Spotlight and hosted by Carmel Fisher, expressed his optimism for the new year while also sharing the company’s recent progress He discussed the company’s core objective- increasing the quality of life, and longevity of people living with Alzheimer’s, dementia, and autism (“ADA”) Bertagna also hinted at potential acquisitions by the company, attributing it to extensive efforts over the past couple of years to clean up its balance sheet He noted that as MetAlert’s revenue per user continues to grow, its margins will increase, ultimately placing the company in…

ThursdayJan 19, 2023 9:00 am

MetAlert, Inc. (MLRT) Signs Letter of Intent to Acquire TrakTec on Synergistic and Complementary Technologies Set to Offer Short and Long-Term Benefits

MetAlert recently signed a Letter of Intent to acquire Florida-based TrakTec in a cash and stock deal worth $4.5 million TrakTec manufactures and sells affordable location awareness technology solutions for consumer, enterprise, and government applications The planned acquisitions will bring on board synergistic and complementary technologies that fit in with MetAlert’s subscription model and existing suite of location-sensitive and tracking solutions The acquisition is also set to offer both short- and long-term benefits, eventually contributing to the company’s efforts to up-list MetAlert (OTC: MLRT), a pioneer in location-sensitive wearable technology products and human and health monitoring devices, is looking to…

TuesdayJan 17, 2023 12:00 pm

India Globalization Capital Inc. (NYSE American: IGC) Announces Beginning of Phase 2 Clinical Trials for Proprietary Drug Candidate in Treating Alzheimer’s

Believed to be the first natural low-doses of THC-based compound to enter human trials for Alzheimer’s IGC-AD1 has the potential to revolutionize the treatment of Alzheimer’s disease The clinical trial is expected to produce data to “help us to further understand the metabolism of IGC-AD1 for a diverse population,” says CEO In a historic first, India Globalization Capital (NYSE American: IGC) has begun Phase 2 clinical trials evaluating its flagship drug candidate, IGC-AD1, for the treatment of agitation in dementia from Alzheimer’s disease (https://nnw.fm/Y1rLN). Company officials noted that, to their knowledge, this is the first natural low-dose THC-based compound to…

TuesdayJan 17, 2023 10:30 am

BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Preclinical Study on Inhaled NanoAb COVID-19 Therapy Shows Elimination of Virus from Lungs

BiondVax is developing a pipeline of nanosized antibody (“NanoAb”) therapies addressing diseases with large underserved medical needs and attractive commercial opportunities BiondVax recently announced results from a preclinical in vivo proof-of-concept study indicating its innovative inhaled NanoAb COVID-19 therapy virtually eliminates viral presence in the lungs and leads to significantly shorter and milder illness BiondVax CEO Amir Reichman presented at the Biotech Showcase Conference, where he discussed recent successful results from the preclinical in vivo study, additional pipeline plans for other NanoAb therapeutics, and the company’s derisked R&D strategy Mainland China is experiencing a fresh wave of COVID-19 infections sweeping…

FridayJan 13, 2023 9:45 am

Wearable Tracking Device Developer MetAlert, Inc. (MLRT) Set to Build on 2022’s Progress to Uplist, Expand Medical Data Offerings

MetAlert recently released its yearend shareholder update letter, covering the past year’s progress, and associated plans for 2023, all focused on helping to monitor the safety and location of dementia patients and other vulnerable individuals Coupled with concerns about patients with Alzheimer’s disease or other brain conditions that may lead toward risks of them wandering, becoming lost or disoriented, or falling, the situation demonstrates an opportunity for remote monitoring of patients’ whereabouts To meet the need, MetAlert developed a pioneering wearable GPS-enabled tracking device a decade ago that unobtrusively slips into wearers’ shoes The company has since expanded the device’s…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports Promising Prophylactic Results from Preclinical Proof-of-Concept NanoAb COVID-19 Study

MetAlert, Inc. (MLRT) Planned Acquisition of TrakTec LLC Adds Superior Radio Frequency-Based Tracking Technology to Portfolio of Location-Based Solutions

Silo Pharma Inc. (NASDAQ: SILO) Provides Update on UCSF Psylocibin Clinical Trial

HeartBeam Inc. (NASDAQ: BEAT) Combats Rising Heart Disease Numbers by Leading Out in Heart-Attack Detection Space

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19

MetAlert, Inc. (MLRT) In Strong Position Entering 2023 According to CEO Patrick Bertagna

MetAlert, Inc. (MLRT) Signs Letter of Intent to Acquire TrakTec on Synergistic and Complementary Technologies Set to Offer Short and Long-Term Benefits

India Globalization Capital Inc. (NYSE American: IGC) Announces Beginning of Phase 2 Clinical Trials for Proprietary Drug Candidate in Treating Alzheimer’s

BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Preclinical Study on Inhaled NanoAb COVID-19 Therapy Shows Elimination of Virus from Lungs

Wearable Tracking Device Developer MetAlert, Inc. (MLRT) Set to Build on 2022’s Progress to Uplist, Expand Medical Data Offerings

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search